Using carbon nanotubes to deliver mRNA for an HIV vaccine
Carbon Nanotube Enabled Delivery of mRNA for an HIV Vaccine Candidate
This study is testing a new type of HIV vaccine that uses tiny carbon tubes to help deliver important instructions to your immune system, with the hope of creating a stronger defense against the virus and ultimately reducing the spread of HIV.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Luna Labs USA, LLC NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10951006 on NIH RePORTER |
What this research studies
This research focuses on developing a novel vaccine for HIV-1 by utilizing carbon nanotubes to effectively deliver mRNA. The approach aims to stimulate the immune system to produce broadly neutralizing antibodies and enhance CD8+ T cell responses, which are crucial for controlling HIV infection. By combining advanced delivery systems with optimized vaccine components, the project seeks to create a more effective immunization strategy against HIV. Patients may benefit from this innovative approach if it leads to a successful vaccine that reduces HIV transmission.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of HIV infection or those living with HIV who may benefit from improved vaccination strategies.
Not a fit: Patients who are already effectively managing their HIV with existing treatments may not see additional benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly lowers the rate of new HIV infections.
How similar studies have performed: While there have been numerous attempts to develop an HIV vaccine, this approach using carbon nanotubes for mRNA delivery is relatively novel and has not been extensively tested in previous studies.
Where this research is happening
Charlottesville, United States
- Luna Labs USA, LLC — Charlottesville, United States (Active)
Researchers
- Principal investigator: Xu, Yang — Luna Labs USA, LLC
- Study coordinator: Xu, Yang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.